Eton Pharma introduces ultra-rare disease product nitisinone capsules

Eton Pharmaceuticals Inc, an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, announced the commercial availability of nitisinone capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Eton is committed to serving patients and families with the rarest of conditions. We are proud to make nitisinone available to the hundreds of patients in the United States and offer full patient and provider support services. We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50 million annual nitisinone market,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

Nitisinone capsules are available exclusively through Optime Care, a specialty pharmacy dedicated to helping patients with rare diseases manage their conditions. Optime Care will administer the Eton Cares Programme in partnership with Eton Pharmaceuticals. The Eton Cares Programme will provide $0 co-pays for all commercially insured patients, as well as prescription fulfillment, insurance benefits investigation, educational support, and financial assistance for qualifying patients.

Clinicians seeking to prescribe nitisinone capsules can e-prescribe by selecting Optime Care as the pharmacy or fax in a patient referral form to 866-318-2990.

Nitisinone is a prescription medicine used to treat adults and children with a hereditary disease called tyrosinemia type 1 (HT-1). Nitisinone should be taken along with a diet limiting tyrosine and phenylalanine.

Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases. The company currently has four FDA-approved rare disease products: Alkindi Sprinkle, Carglumic Acid, Betaine Anhydrous, and Nitisinone.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!